Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.16 +0.58%
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
MLKN, KBH, WOR, More
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
MLKN, KBH, WOR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67 million.
GUIDANCE:
Vanda Pharmaceuticals sees Q3 2022 revenue of $240-280 million, versus the consensus of $265.1 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Bernstein SocGen Group Upgrades Engie SA (ENGI:FP) (ENGIY) to Outperform
- Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
